Inflammatory bowel disease affects roughly 230 out of every 100,000 people worldwide, making it one of the more common chronic digestive conditions globally. In the United States alone, between 2.4 and 3.1 million people are living with IBD, depending on how cases are counted. Those numbers have been climbing steadily for decades, and the disease is now spreading into parts of the world where it was once rare.
IBD Prevalence in the United States
The CDC estimates between 2.4 and 2.8 million IBD patients based on insurance claims data, while national health surveys put the figure closer to 3.1 million adults. The gap reflects how many people live with IBD but don’t show up consistently in billing records, whether because of gaps in insurance, infrequent doctor visits, or mild symptoms that don’t trigger claims.
White Americans have the highest prevalence at about 812 per 100,000, followed by Black Americans at 504, Hispanic Americans at 458, and Asian Americans at 403 per 100,000. Those disparities have narrowed over time, and IBD is no longer considered a condition that primarily affects white populations. Prevalence among Black and Hispanic communities has been rising, and clinicians are diagnosing it more frequently across all racial and ethnic groups.
Crohn’s Disease vs. Ulcerative Colitis
IBD is an umbrella term covering two main conditions: Crohn’s disease and ulcerative colitis. Ulcerative colitis is slightly more common. In one of the longest-running population studies, from Olmsted County, Minnesota, ulcerative colitis had a prevalence of about 286 per 100,000 people compared to 247 per 100,000 for Crohn’s disease. New diagnoses each year are also comparable, with ulcerative colitis at roughly 12.2 cases per 100,000 person-years and Crohn’s disease at 10.7.
The two conditions behave differently. Ulcerative colitis is limited to the colon and rectum, while Crohn’s can affect any part of the digestive tract from mouth to anus and tends to penetrate deeper into the intestinal wall. Despite these differences, their overall frequency in the population is close enough that neither is considered rare.
When IBD Is Most Often Diagnosed
IBD follows a bimodal pattern, meaning diagnoses cluster around two age windows. The primary peak is between ages 30 and 40, which is when most people first develop symptoms. A smaller second peak occurs between 60 and 70. This second wave is sometimes called elderly-onset IBD and can be trickier to diagnose because symptoms like diarrhea, cramping, and fatigue overlap with other conditions common in older adults.
Among children, IBD prevalence was slightly higher in boys. In adults, the balance shifts, with women slightly more likely to carry a diagnosis. The reasons aren’t fully understood, but hormonal factors and differences in immune regulation likely play a role.
IBD in Children
About 14,000 children and adolescents worldwide were newly diagnosed with IBD in 2021, up from roughly 12,300 in 1990. That’s a 13.8% increase in the raw number of cases over three decades, though the rate per population has remained relatively stable globally. The overall incidence didn’t meaningfully change between 2017 and 2021.
Regional differences tell a more dramatic story. In wealthier countries, pediatric IBD rates have actually declined slightly, while low-income and newly industrialized regions have seen significant increases. East Asia, for example, saw some of the sharpest rises. Countries like Denmark and Canada have reported annual growth rates in pediatric IBD exceeding 8%, likely driven by better detection and reporting alongside genuine increases in disease.
A Global Shift Toward Industrializing Countries
For most of the twentieth century, IBD was considered a Western disease, concentrated in North America, Europe, and parts of Oceania. That picture has changed dramatically. Since 2000, newly industrialized regions in Latin America, East Asia, and the Middle East have reported sharp increases in IBD diagnoses, particularly ulcerative colitis, with Crohn’s disease following behind.
Researchers at Nature described this shift using an epidemiological staging model. Most Western countries are now in a later stage where incidence has leveled off but prevalence keeps growing because people live with IBD for decades. Meanwhile, many countries in Asia and Latin America are in an earlier stage of rapidly rising new diagnoses, similar to what the West experienced in the mid-twentieth century. Parts of Africa still see only sporadic cases, but that’s expected to change as urbanization, dietary shifts, and improved diagnostic access continue.
China illustrates the trajectory well. IBD incidence there is projected to keep climbing until around 2030, when it’s expected to reach nearly 60,000 new cases per year before leveling off. At that point, China will enter what researchers call a “compounding prevalence” stage, where the total number of people living with IBD grows rapidly even as new diagnoses stabilize, simply because existing patients accumulate.
The Financial Weight of IBD
IBD is expensive to manage. In the United States, total healthcare spending on IBD patients reached an estimated $25.4 billion in 2016. That figure captures hospital visits, medications, imaging, and outpatient care. On a per-patient basis, annual spending more than doubled over two decades, rising from about $5,700 in the mid-1990s to over $14,000 by 2016. Much of that increase is driven by biologic therapies, which are highly effective but costly.
These costs don’t capture the full burden. People with IBD often miss work during flares, may need to reduce hours, or face limitations in daily activities that don’t show up in healthcare spending figures. For a condition that typically strikes during prime working years and lasts a lifetime, the cumulative personal and economic impact is substantial.